O’Melveny represented Pharmaron Beijing Co., Ltd. (300759.SZ and 3759.HK), in its approximately HK$4.6 billion (approximately US$588 million) dual primary listing and H share offering in Hong…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
